Lu AA21004

DRUG3 trials

Sponsors

H. Lundbeck A/S, Takeda

Conditions

Generalized Anxiety DisorderHealthyMajor Depressive Disorder

Phase 1

Pharmacokinetic Properties of Lu AA21004 (Vortioxetine) in Healthy Young Chinese Men and Women

CompletedNCT01676571

H. Lundbeck A/SHealthy

Start: 2012-10-31Updated: 2013-01-16

Phase 3

Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder

CompletedNCT00788034

H. Lundbeck A/SGeneralized Anxiety Disorder

Start: 2008-10-31End: 2010-07-31Updated: 2015-06-23

Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder

CompletedNCT01395147

TakedaMajor Depressive Disorder

Start: 2011-07-31End: 2013-05-31Updated: 2013-11-05

Related Papers

Safety of Vortioxetine in Patients With Depression: A Post‐Marketing Surveillance Study of Intracranial Hemorrhage in a Japanese Health Insurance Claims Database

Neuropsychopharmacology Reports2025-12-25

Pharmacokinetics and Safety of Vortioxetine in the Chinese Population

Advances in Therapy2019-09-2410 citations

Efficacy of vortioxetine in working patients with generalized anxiety disorder

CNS Spectrums2017-10-3015 citations